A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors
<h4>Purpose</h4> Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovitinib and was applied retrospe...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468037/?tool=EBI |
| _version_ | 1797692811705843712 |
|---|---|
| author | Steen Knudsen Anker Hansen Marie Foegh Steen Petersen Hana Mekonnen Lin Jia Preeti Shah Victoria Martin Gregory Frykman Roberto Pili |
| author_facet | Steen Knudsen Anker Hansen Marie Foegh Steen Petersen Hana Mekonnen Lin Jia Preeti Shah Victoria Martin Gregory Frykman Roberto Pili |
| author_sort | Steen Knudsen |
| collection | DOAJ |
| description | <h4>Purpose</h4> Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovitinib and was applied retrospectively. <h4>Patients and methods</h4> Archival tumor samples were obtained from consenting patients in a phase 3 trial comparing dovitinib to sorafenib in renal cell carcinoma patients and the DRP-Dovitinib was applied. The biomarker algorithm combines the expression of 58 messenger RNAs relevant to the in vitro sensitivity or resistance to dovitinib, including genes associated with FGFR, PDGF, VEGF, PI3K/Akt/mTOR and topoisomerase pathways as well as ABC drug transport, and provides a likelihood score between 0–100%. <h4>Results</h4> The DRP-Dovitinib divided the dovitinib treated RCC patients into two groups, sensitive (n = 49, DRP score >50%) or resistant (n = 86, DRP score ≤ 50%) to dovitinib. The DRP sensitive population was compared to the unselected sorafenib arm (n = 286). Median progression-free survival (PFS) was 3.8 months in the DRP sensitive dovitinib arm and 3.6 months in the sorafenib arm (hazard ratio 0.71, 95% CI 0.51–1.01). Median overall survival (OS) was 15.0 months in the DRP sensitive dovitinib arm and 11.2 months in the sorafenib arm (hazard ratio 0.69, 95% CI 0.48–0.99). The observed clinical benefit increased with increasing DRP score. At a cutoff of 67% the median OS was 20.6 months and the median PFS was 5.7 months in the dovitinib arm. The results were confirmed in five smaller phase II trials of dovitinib which showed a similar trend. <h4>Conclusion</h4> The DRP-Dovitinib shows promise as a potential biomarker for identifying advanced RCC patients most likely to experience clinical benefit from dovitinib treatment, subject to confirmation in an independent prospective trial of dovitinib in RCC patients. |
| first_indexed | 2024-03-12T02:32:59Z |
| format | Article |
| id | doaj.art-959bcf4274864e8ba19888a0ae507918 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-03-12T02:32:59Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-959bcf4274864e8ba19888a0ae5079182023-09-05T05:31:45ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01188A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumorsSteen KnudsenAnker HansenMarie FoeghSteen PetersenHana MekonnenLin JiaPreeti ShahVictoria MartinGregory FrykmanRoberto Pili<h4>Purpose</h4> Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovitinib and was applied retrospectively. <h4>Patients and methods</h4> Archival tumor samples were obtained from consenting patients in a phase 3 trial comparing dovitinib to sorafenib in renal cell carcinoma patients and the DRP-Dovitinib was applied. The biomarker algorithm combines the expression of 58 messenger RNAs relevant to the in vitro sensitivity or resistance to dovitinib, including genes associated with FGFR, PDGF, VEGF, PI3K/Akt/mTOR and topoisomerase pathways as well as ABC drug transport, and provides a likelihood score between 0–100%. <h4>Results</h4> The DRP-Dovitinib divided the dovitinib treated RCC patients into two groups, sensitive (n = 49, DRP score >50%) or resistant (n = 86, DRP score ≤ 50%) to dovitinib. The DRP sensitive population was compared to the unselected sorafenib arm (n = 286). Median progression-free survival (PFS) was 3.8 months in the DRP sensitive dovitinib arm and 3.6 months in the sorafenib arm (hazard ratio 0.71, 95% CI 0.51–1.01). Median overall survival (OS) was 15.0 months in the DRP sensitive dovitinib arm and 11.2 months in the sorafenib arm (hazard ratio 0.69, 95% CI 0.48–0.99). The observed clinical benefit increased with increasing DRP score. At a cutoff of 67% the median OS was 20.6 months and the median PFS was 5.7 months in the dovitinib arm. The results were confirmed in five smaller phase II trials of dovitinib which showed a similar trend. <h4>Conclusion</h4> The DRP-Dovitinib shows promise as a potential biomarker for identifying advanced RCC patients most likely to experience clinical benefit from dovitinib treatment, subject to confirmation in an independent prospective trial of dovitinib in RCC patients.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468037/?tool=EBI |
| spellingShingle | Steen Knudsen Anker Hansen Marie Foegh Steen Petersen Hana Mekonnen Lin Jia Preeti Shah Victoria Martin Gregory Frykman Roberto Pili A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors PLoS ONE |
| title | A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors |
| title_full | A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors |
| title_fullStr | A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors |
| title_full_unstemmed | A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors |
| title_short | A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors |
| title_sort | novel drug specific mrna biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468037/?tool=EBI |
| work_keys_str_mv | AT steenknudsen anoveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT ankerhansen anoveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT mariefoegh anoveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT steenpetersen anoveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT hanamekonnen anoveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT linjia anoveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT preetishah anoveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT victoriamartin anoveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT gregoryfrykman anoveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT robertopili anoveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT steenknudsen noveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT ankerhansen noveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT mariefoegh noveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT steenpetersen noveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT hanamekonnen noveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT linjia noveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT preetishah noveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT victoriamartin noveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT gregoryfrykman noveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors AT robertopili noveldrugspecificmrnabiomarkerpredictorforselectionofpatientsrespondingtodovitinibtreatmentofadvancedrenalcellcarcinomaandothersolidtumors |